Navigation Links
Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research
Date:10/7/2009

SEATTLE, Oct. 7 /PRNewswire/ -- The National Heart, Lung and Blood Institute has awarded a total of $16.7 million to Irwin Bernstein, M.D., and Beverly Torok-Storb, Ph.D., both members of the Clinical Research Division at Fred Hutchinson Cancer Research Center. The Hutchinson Center grants represent part of a $170 million effort involving 18 teams of research scientists dedicated to developing stem- and progenitor-cell tools and therapies.

The seven-year awards create the NHLBI Progenitor Cell Biology Consortium, which assembles nine research hubs with multidisciplinary teams of principal investigators and an administrative coordinating center.

While a stem cell can renew itself indefinitely or differentiate, a progenitor cell can only divide a limited number of times and is often more constrained than a stem cell in the kinds of cells it can become. Given the potential of these cells for clinical applications, the consortium aims to identify and characterize progenitor cell lines, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new clinical strategies to address the unique challenges presented by the transplantation of these cells.

Torok-Storb, along with Fred Hutchinson/University of Washington Cancer Consortium colleagues, will collaborate with Mortimer Poncz, M.D., of Children's Hospital of Philadelphia to develop molecular- and cell-based therapies for a range of blood diseases, with an initial focus on the delayed recovery of blood-clotting platelets following stem-cell transplantation, a life-threatening complication called thrombocytopenia.

The partner institutions will focus on two complementary strategies to address delayed platelet production. With their $8.2 million grant, Torok-Storb's team will develop reagents that can be administered to patients to stimulate the differentiation and proliferation of precursor cells into platelets. The Philadelphia group will work to generate "ex vivo," or outside the body, platelets and their precursors from embryonic stem cells for use as cell therapy.

Bernstein, along with Hutchinson Center/UW Cancer Consortium researchers and the University of Pennsylvania's Edward Morrisey, Ph.D., is using his $8.5 million award to determine how certain signaling pathways - ordered sequences of biochemical reactions inside cells - affect cardiac and blood-forming cell development and cardiac regeneration and repair. The team will also study whether these pathways can be harnessed for therapeutic applications. Drawing on Bernstein's success in expanding cord-blood stem cells, the researchers hope to refine methods for deriving therapeutically useful numbers of cells for transplantation and other treatments.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

    CONTACT
    Kristen Woodward
    206-667-2896
    kwoodwar@fhcrc.org

SOURCE Fred Hutchinson Cancer Research Center


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
6. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... ALTO, Calif. , March 29, 2017 Varian ... it will report results for the second quarter of fiscal ... April 26, 2017.  The news release will be followed by ... PT.  The news release and a link to the conference ... www.varian.com/investor .  To access the teleconference call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Sports Brand EXOUS Bodygear announced today a special sale price for the ... days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... (regular retail price $19.97). , The special promotional prices are to help individuals get ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... now have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries ... Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing these ...
Breaking Medicine News(10 mins):